Placeholder Banner

Importation Scheme Will Jeopardize Patient Health, Do Little to Lower Drug Costs

“Patients deserve access to the medicines they need with out-of-pocket costs they can afford. Under no circumstance should we risk patient safety to achieve this goal, yet that’s exactly what this dangerous importation scheme will do."

December 18, 2019
Media Contact
Author-Profile-Andrew-Segerman

Washington, DC (December 18, 2019) – Following the release of the Trump administration’s drug importation proposal, BIO’s President and CEO Jim Greenwood issued the following statement:

“Patients deserve access to the medicines they need with out-of-pocket costs they can afford. Under no circumstance should we risk patient safety to achieve this goal, yet that’s exactly what this dangerous importation scheme will do. The idea that this plan will result in savings for patients at the pharmacy counter is a talking point that’s been debunked by nonpartisan budget experts and past FDA commissioners who served under both Republican and Democratic administrations.

“Following the recent vote on Speaker Pelosi’s extreme drug pricing plan, today’s announcement is the latest empty gesture from our elected lawmakers who want us to believe they’re serious about lowering patients’ prescription drug costs. It’s time Congress and the administration delivered a holistic solution that protects the health and well-being of patients and ensures medicines are affordable.”

Learn more:

 

###

Discover More
Washington, D.C. (January 15, 2020) – BIO President and CEO Jim Greenwood released the following statement today regarding the signing of Phase One of the trade agreement with China: “Trade issues with China have long been a priority for BIO and…
Today, the Sustainable Aviation Fuels (SAF) Producers Group together with the Biotechnology Innovation Organization (BIO) and the Low Carbon Fuels Coalition (LCFC) issued the following statement commending Alaska Airlines’ support for including…
The Biotechnology Innovation Organization (BIO) released the following statement in response to House passage of the revised USMCA: “The revised USMCA was a huge missed opportunity to create a positive framework for a dynamic and leading…